New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.
ICICI Securities is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 32700 in its ...
We recently compiled a list of the Billionaire Ken Fisher’s Top 10 High Growth Stock Picks. In this article, we are going to ...
USPTO mass resignation concerns; INPI president interview; WTR summit speaker line-up; and much more
Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself ...
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback